Telmisartan vs Vesugen
A side-by-side research comparison of Telmisartan and Vesugen across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Telmisartan | Vesugen |
|---|---|---|
| Full name | Telmisartan (ARB / Partial PPAR-gamma Agonist) | Vesugen (Lys-Glu-Asp Vascular Bioregulator) |
| Category | Cardiovascular | Cardiovascular |
| Status | FDA-approved drug | Research compound (peptide bioregulator) |
| Mechanism | Blocks the angiotensin II type 1 (AT1) receptor to lower blood pressure and reduce vascular inflammation, while also acting as a partial PPAR-gamma agonist that improves insulin sensitivity, lipid handling, and mitochondrial biogenesis. | As a signal peptide (Lys-Glu-Asp), it is proposed to enter cells and regulate gene expression in vascular tissue, supporting endothelial function, vascular tone, and normal vessel-wall maintenance. |
| Molecular weight | 514.62 Da | ~390 Da |
| Half-life | ~24 hours | Short (peptide) |
| Bioavailability | ~42-58% oral | Oral (encapsulated) or subcutaneous |
| Typical dose | 20-80 mg per day | ~1-2 capsules/day or short injectable courses |
| Frequency | Once daily | Once daily |
| Route | Oral tablet | Oral capsule or subcutaneous |
Telmisartan reported benefits
- Blood pressure control
- PPAR-gamma metabolic benefits
- Improved insulin sensitivity
- Vascular anti-inflammatory effects
- Cardio- and reno-protection
- 24-hour coverage
Vesugen reported benefits
- Vascular/endothelial support
- Proposed vascular tissue regulation
- Short course-based protocol
- Part of bioregulator longevity systems
Related comparisons
Research and educational reference only. Not medical advice.